菲沃泰：2025年前三季度净利润约2898万元

Group 1 - The core viewpoint of the article highlights the financial performance of Fivotech, with a revenue of approximately 367 million yuan for the first three quarters of 2025, representing a year-on-year increase of 6% [1] - The net profit attributable to shareholders for the same period is about 28.98 million yuan, showing a year-on-year growth of 6.45% [1] - As of the report date, Fivotech's market capitalization stands at 8 billion yuan [2] Group 2 - The article discusses the broader context of the Chinese innovative drug market, noting that overseas licensing has generated 80 billion USD this year [2] - It raises questions about the disparity between the hot secondary market for biomedicine and the cooling fundraising environment in the primary market [2]